Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
ID: PS75N95024R00094_2Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Medicinal and Botanical Manufacturing (325411)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/ddaf430bb5494ac2b358fcd78137880a/view
Timeline
    Description

    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug substances. The primary objective is to ensure the Division of Preclinical Innovation (DPI) receives drug substances of adequate quality and quantity to support preclinical and Investigational New Drug (IND)-enabling studies, adhering to current Good Manufacturing Practice (cGMP) standards. This procurement is crucial for advancing therapeutics from preclinical stages to market readiness, emphasizing a multidisciplinary approach and compliance with regulatory requirements throughout the drug development pipeline. The Request for Proposals (RFP) is expected to be released on or about October 4, 2024, with contract awards anticipated in the second quarter of FY2025. Interested parties may contact Samson Shifaraw at samson.shifaraw@nih.gov for further information.

    Point(s) of Contact
    Samson Shifaraw
    (301) 480-7153
    samson.shifaraw@nih.gov
    Files
    Title
    Posted
    1-SOW.pdf
    The document outlines the Statement of Work (SOW) for Chemistry, Manufacturing, and Controls (CMC) pertaining to drug substance development by the Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS), NIH. TDB aims to advance therapeutics from preclinical stages to investigational new drug (IND) applications. The scope covers CMC services necessary for drug substance quality and quantity in preclinical studies, involving the development and validation of processes for small molecules, peptides, oligonucleotides, and biopharmaceuticals, adhering to current Good Manufacturing Practice (cGMP). General requirements include contract administration, project management, collaboration, quality management, and compliance with regulatory standards. The document emphasizes the necessity for a multidisciplinary approach, providing trained personnel, maintaining quality assurance, and facilitating independent audits. The tasks encompass process development, analytical method validation, and ensuring the quality and stability of drug substances, with sustainability considerations in supply chain management. The purpose of this SOW is to ensure that the complex process of therapeutic development is carried out effectively, promoting innovation and adhering to regulatory guidelines throughout the drug development pipeline.
    Similar Opportunities
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Biological Therapeutics Product Development Subject Matter Expert Consultants
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), is seeking proposals for consulting services from subject matter expert (SME) consultants to support the development of biological therapeutics. The objective of this procurement is to engage SMEs who can provide technical recommendations across various phases of drug discovery and development, including chemistry, regulatory affairs, and clinical trial design, particularly for novel therapeutics aimed at neurological disorders and rare genetic conditions. This initiative is crucial for advancing NIH drug discovery programs and ensuring that innovative therapeutic solutions progress efficiently to clinical evaluation. Interested vendors must submit their proposals by January 27, 2025, and can direct inquiries to Shayna Simpson at shayna.simpson@nih.gov or Kelly Dempsey at kelly.dempsey@nih.gov. The contract is expected to span one year with two optional extensions, and the anticipated performance period is from April 1, 2025, to March 30, 2026.
    SOURCES SOUGHT: Mass Spectrometry Reagents
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), is seeking qualified small business sources for the procurement of specialized Mass Spectrometry Reagents aimed at advancing research on Alzheimer’s Disease and related dementias. The objective is to establish a national resource of isogenic induced pluripotent stem cell (iPSC) lines to study genetic mutations associated with these diseases, thereby accelerating mechanistic discovery. This procurement is critical for enhancing the understanding of Alzheimer’s disease mechanisms and includes specific requirements for HPLC columns and related supplies, with the first delivery expected by July 7, 2025, and additional options extending to July 2027. Interested parties should submit their capability statements to Rashiid Cummins at Rashiid.Cummins@nih.gov by January 21, 2025, at 3:00 PM Eastern Time.
    CIVICs Data Management and Coordinating Center (DMCC)
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide services for the renewal of the CIVICs Data Management and Coordinating Center (DMCC). The DMCC will support the CIVICs program by managing data, conducting analyses, and facilitating communication and coordination among various stakeholders, with a focus on advancing influenza vaccine research and development. This initiative is critical for enhancing the immunogenicity and durability of seasonal influenza vaccines and involves the operation of a scalable data management system, maintenance of public and private portals, and comprehensive program coordination. Interested parties must submit their tailored Capability Statements by 3:00 PM (Eastern Time) on January 23, 2025, to Maribel Miranda at maribel.miranda@nih.gov, with the anticipated contract award date around July 2026.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families that pose a pandemic threat. This initiative is critical for addressing public health challenges and enhancing biodefense capabilities, with an estimated funding of $28.5 million available for awards in fiscal year 2026. Proposals for Research Area 002 are due by January 21, 2025, while those for Research Area 001 must be submitted by February 21, 2025; interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    A--Clinical Research Operations and Management (CROMS)
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the Clinical Research Operations and Management Services (CROMS) contract. This procurement aims to enhance the oversight and efficiency of clinical studies by providing essential systems, tools, and expert resources for data management, site monitoring, and regulatory compliance. The contract is crucial for ensuring high-quality research while adhering to strict federal regulations regarding human subjects, data privacy, and security protocols. The performance period is set from September 30, 2025, to September 29, 2026, with options extending through 2030. Interested parties can reach out to Natalie Bruning at natalie.bruning@nih.gov or Tara C. Knox at knoxt@nhlbi.nih.gov for further details.
    Long Read Sequencing Kits
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the procurement of Long Read Sequencing Kits, specifically Oxford Nanopore brand or equivalent items, to support research on neurodegenerative diseases. The acquisition aims to supply the Center for Alzheimer’s Disease and Related Dementias with kits that will facilitate the identification of causative genes linked to Alzheimer's Disease and related disorders, utilizing long-read sequencing technology. This procurement is critical for advancing research in understanding and treating neurodegenerative diseases, with an anticipated delivery of the first order by September 30, 2025, and options for additional orders in subsequent years. Interested vendors must submit their quotations by 12:00 p.m. EST on January 24, 2025, to Andrea Clay at amcgee@nida.nih.gov, referencing Solicitation Number 75N95025Q00095.
    A--Biomedical Computing Support Services
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for Biomedical Computing Support Services to assist in ongoing cancer research initiatives. The procurement aims to provide comprehensive computing services that facilitate the analysis of high-dimensional biomedical data, supporting both domestic and international studies within the Division of Cancer Epidemiology and Genetics (DCEG). This opportunity is critical for enhancing cancer research capabilities, with an estimated contract value ranging from $3,000 to $147 million over a performance period of five years, beginning September 16, 2025, with a potential five-year extension. Interested offerors must submit their proposals by January 6, 2025, and can direct inquiries to Antoinette C. Robinson at antoinette.robinson@nih.gov or by phone at +1 240 276 5823.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    A--Data Coordinating Center (DCC) for the Best Pharmaceuticals for Children Act (B
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Institute of Child Health and Human Development (NICHD), is seeking qualified small businesses to support the Data Coordinating Center (DCC) for the Best Pharmaceuticals for Children Act (BPCA). The primary objective of this procurement is to provide comprehensive data management, analysis, and regulatory reporting services for pediatric clinical trials, ensuring compliance with FDA regulations and facilitating data submission to the FDA and the NICHD Data Repository. This initiative is crucial for enhancing pediatric health outcomes by addressing therapeutic gaps and conducting necessary clinical studies, as mandated by the reauthorized BPCA. Interested parties must submit their capability statements by January 28, 2025, and can contact Deborah Brock at Deborah.Brock@nih.gov for further information.